Rebecca Araujo

DocwireNews

<p>The American College of Rheumatology (ACR) and the Vasculitis Foundation released three new <a href="https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Vasculitis">clinical practice guidelines</a> for treating and managing systemic vasculitis. Sharon A. Chung, MD, lead investigator behind the guidelines and Director of the Vasculitis Clinic at the University of California, San Francisco, spoke with DocWire News about the latest recommendations and the most important takeaways from the new guidance.<p>&ldquo;These guidelines were developed to provide health care practitioners a framework for treating patients with systemic vasculitis, and as well as to provide guidance on important topics to be considered for the management of these diseases,&rdquo; said Dr. Chung.</p><h2>What&rsquo;s Covered in the Guidelines?</h2><p>Published online and in <em>Arthritis &amp; Rheumatology,</em> the ACR guidelines offer treatment direction for &ldquo;the most common types of systemic vasculitis treated by rheumatologists,&rdquo; Dr. Chung told DocWire.</p><p>When asked what prompted the development of these guidelines, Dr. Chung responded, &ldquo;The systemic vasculitides are rare diseases, and many rheumatologists may not have substantial experience treating patients with these diseases. Concurrently, more randomized clinical trials of treatments for systemic vasculitis have been published, and thus patients with vasculitis have more treatment options.&rdquo;</p><p>She explains, &ldquo;These guidelines provide recommendations for seven types of vasculitis:</p><ul>
<li>Large vessel vasculitis: Giant cell arteritis and Takayasu arteritis</li>
<li>Medium vessel vasculitis: polyarteritis nodosa</li>
<li>ANCA-associated vasculitis: granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis for polyangiitis.&rdquo;</li>
</ul><p>The guidelines offer information regarding all stages of care for these conditions. &ldquo;For each type of vasculitis, we provide recommendations regarding the use of diagnostic testing (e.g., imaging, laboratory studies, and/or biopsies), preferred treatments, and management considerations (e.g., laboratory monitoring, routine imaging studies, and physical therapy),&rdquo; said Dr. Chung.</p><h2>Major Clinical Takeaways</h2><p>Biologics are an important topic covered in the recommendations. &ldquo;The guidelines support the increasing use of biologics for the management of systemic vasculitides,&rdquo; said Dr. Chung. &ldquo;Examples are support for the use of:</p><ul>
<li>tocilizumab in giant cell arteritis</li>
<li>TNF-alpha inhibitors in Takayasu arteritis</li>
<li><a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/fluorescence-optical-imaging-is-able-to-effectively-discriminate-between-rheumatoid-arthritis-patients-with-and-without-need-of-rituximab-retherapy/">rituximab</a> for granulomatosis with polyangiitis and microscopic polyangiitis</li>
<li>mepolizumab for eosinophilic granulomatosis with polyangiitis.&rdquo;</li>
</ul><p>With these recommendations, physicians may be less hesitant to use new biologics in practice. &ldquo;The efficacy of many of these agents for vasculitis have only been recognized in the past few years, and thus practitioners may have some reluctance to use them,&rdquo; said Dr. Chung.</p><p>Another key takeaway is &ldquo;support for minimizing glucocorticoid (e.g., prednisone) exposure to decrease glucocorticoid toxicity,&rdquo; said Dr. Chung.</p><p>She adds, &ldquo;Lastly, we advocate for the use of imaging to help identify extent of disease for both large and medium vessel vasculitis (polyarteritis nodosa). &ldquo;</p><h2>Looking Forward</h2><p>Dr. Chung also commented on next steps and future areas of research in the treatment of vasculitis. She explains, &ldquo;Future areas of research that would facilitate management of these conditions include identification of biomarkers or other non-invasive tests that can quantify disease activity or predict disease outcomes. Trials are needed to inform the optimal duration of therapy, the comparative effectiveness of therapies we currently use, and new treatments with less toxicity. Long-term studies are needed to understand how our therapies change the course of disease and their safety. We hope that with additional knowledge in these areas, we will be able to update these recommendations in the future.&rdquo;</p></p>


Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

New Vasculitis Treatment Guidelines: What Rheumatologists Should Know

Rheumatology

The American College of Rheumatology (ACR) and the Vasculitis Foundation released three new clinical practice guidelines for treating and managing systemic vasculitis. Sharon ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe